NO-donating aspirin inhibits both the expression and catalytic activity of inducible nitric oxide synthase in HT-29 human colon cancer cells

Biochemical Pharmacology

Volumn 70, Issue 7, 2005, Pages 993-1000

  Spiegel, Adam ^a   Hundley, Thomas R ^a   Chen, Jie ^a   Gao, Jianjun ^a   Ouyang, Nengtai ^a   Liu, Xiaoping ^a   Go, Mae F ^b   Tsioulias, George J ^a   Kashfi, Khosrow ^c   Rigas, Basil ^a  

^a STONY BROOK UNIVERSITY   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c CITY UNIVERSITY OF NEW YORK MEDICAL SCHOOL   (United States)

Author keywords

Aspirin; Colon adenocarcinoma cells; Colon cancer; HT 29 human; Nitric oxide synthase; Nitric oxide releasing aspirin; NOS2

Indexed keywords

2 (ACETYLOXY)BENZOIC ACID 4 (NITROOXYMETHYL)PHENYL ESTER; ACETYLSALICYLIC ACID DERIVATIVE; INDUCIBLE NITRIC OXIDE SYNTHASE; MESSENGER RNA; NCX 4040; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CANCER INHIBITION; COLON ADENOCARCINOMA; CONTROLLED STUDY; CULTURE MEDIUM; DRUG EFFECT; DRUG STRUCTURE; ENZYMATIC ASSAY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME MECHANISM; HUMAN; HUMAN CELL; IC 50; PRIORITY JOURNAL; STEADY STATE;

ADENOCARCINOMA; ASPIRIN; BASE SEQUENCE; CATALYSIS; COLONIC NEOPLASMS; DNA PRIMERS; HT29 CELLS; HUMANS; NITRIC OXIDE DONORS; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; RNA, MESSENGER;

EID: 24344478210     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2005.06.027     Document Type: Article

References (37)

1. Cancer facts and figures 2003. American Cancer Society, Atlanta, GA, 2003.
2. K. Krishnan, M.T. Ruffin, and D.E. Brenner Chemoprevention for colorectal cancer Crit Rev Oncol Hematol 33 3 2000 199 219
3. M.J. Thun, S.J. Henley, and C. Patrono Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues J Natl Cancer Inst 94 4 2002 252 266
4. S.J. Shiff, and B. Rigas Nonsteroidal anti-inflammatory drugs and colorectal cancer: evolving concepts of their chemopreventive actions Gastroenterology 113 6 1997 1992 1998
5. J.A. Baron, B.F. Cole, R.S. Sandler, R.W. Haile, D. Ahnen, and R. Bresalier A randomized trial of aspirin to prevent colorectal adenomas N Engl J Med 348 10 2003 891 899
6. R.S. Sandler, S. Halabi, J.A. Baron, S. Budinger, E. Paskett, and R. Keresztes A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer N Engl J Med 348 10 2003 883 890
7. Y. Rayyan, J. Williams, and B. Rigas The role of NSAIDs in the prevention of colon cancer Cancer Invest 20 7-8 2002 1002 1011
8. L.J. Ignarro Nitric oxide as a unique signaling molecule in the vascular system: a historical overview J Physiol Pharmacol 53 4 Pt 1 2002 503 514
9. O.W. Griffith, and D.J. Stuehr Nitric oxide synthases: properties and catalytic mechanism Annu Rev Physiol 57 1995 707 736
10. C.V. Rao Nitric oxide signaling in colon cancer chemoprevention Mutat Res 555 1-2 2004 107 119
11. N. Yagihashi, H. Kasajima, S. Sugai, K. Matsumoto, Y. Ebina, and T. Morita Increased in situ expression of nitric oxide synthase in human colorectal cancer Virchows Arch 436 2 2000 109 114
12. S. Ambs, W.G. Merriam, W.P. Bennett, E. Felley-Bosco, M.O. Ogunfusika, and S.M. Oser Frequent nitric oxide synthase-2 expression in human colon adenomas: implication for tumor angiogenesis and colon cancer progression Cancer Res 58 2 1998 334 341
13. B. Rigas, and K. Kashfi Nitric-oxide-donating NSAIDs as agents for cancer prevention Trends Mol Med 10 7 2004 324 330
14. K. Kashfi, S. Borgo, J.L. Williams, J. Chen, J. Gao, and A. Glekas Positional isomerism markedly affects the growth inhibition of colon cancer cells by nitric oxide-donating aspirin in vitro and in vivo J Pharmacol Exp Ther 312 3 2005 978 988
15. P. Del Soldato, R. Sorrentino, and A. Pinto NO-aspirins: a class of new anti-inflammatory and antithrombotic agents Trends Pharmacol Sci 20 8 1999 319 323
16. J.L. Wallace, and P. Del Soldato The therapeutic potential of NO-NSAIDs Fundam Clin Pharmacol 17 1 2003 11 20
17. S. Fiorucci, L. Santucci, P. Gresele, R.M. Faccino, P. Del Soldato, and A. Morelli Gastrointestinal safety of NO-aspirin (NCX-4016) in healthy human volunteers: a proof of concept endoscopic study Gastroenterology 124 3 2003 600 607
18. J.L. Williams, S. Borgo, I. Hasan, E. Castillo, F. Traganos, and B. Rigas Nitric oxide-releasing nonsteroidal anti-inflammatory drugs (NSAIDs) alter the kinetics of human colon cancer cell lines more effectively than traditional NSAIDs: implications for colon cancer chemoprevention Cancer Res 61 8 2001 3285 3289
19. K. Kashfi, Y. Ryann, L.L. Qiao, J.L. Williams, J. Chen, and P. Del Soldato Nitric oxide-donating nonsteroidal anti-inflammatory drugs inhibit the growth of various cultured human cancer cells: evidence of a tissue type-independent effect J Pharmacol Exp Ther 303 3 2002 1273 1282
20. R. Yeh, J. Chen, J.L. Williams, M. Baluch, T.R. Hundley, and R.E. Rosenbaum NO-donating nonsteroidal antiinflammatory drugs (NSAIDs) inhibit colon cancer cell growth more potently than traditional NSAIDs: a general pharmacological property? Biochem Pharmacol 67 12 2004 2197 2205
21. A.W. Bak, W. McKnight, P. Li, P. Del Soldato, A. Calignano, and G. Cirino Cyclooxygenase-independent chemoprevention with an aspirin derivative in a rat model of colonic adenocarcinoma Life Sci 62 23 1998 L367 L373
22. J.L. Williams, N. Nath, J. Chen, T.R. Hundley, J. Gao, and L. Kopelovich Growth inhibition of human colon cancer cells by nitric oxide (NO)-donating aspirin is associated with cyclooxygenase-2 induction and beta-catenin/T-cell factor signaling, nuclear factor-kappaB, and NO synthase 2 inhibition: implications for chemoprevention Cancer Res 63 22 2003 7613 7618
23. V. Kozoni, G. Tsioulias, S. Shiff, and B. Rigas The effect of lithocholic acid on proliferation and apoptosis during the early stages of colon carcinogenesis: differential effect on apoptosis in the presence of a colon carcinogen Carcinogenesis 21 5 2000 999 1005
24. K. Kashfi, and G.A. Cook Proteinase treatment of intact hepatic mitochondria has differential effects on inhibition of carnitine palmitoyltransferase by different inhibitors Biochem J 282 Pt 3 1992 909 914
25. G.A. Cook, and M.D. Lappi Carnitine palmitoyltransferase in the heart is controlled by a different mechanism than the hepatic enzyme Mol Cell Biochem 116 1-2 1992 39 45
26. H.E. Marshall, D.T. Hess, and J.S. Stamler S-nitrosylation: physiological regulation of NF-kappaB Proc Natl Acad Sci USA 101 24 2004 8841 8842
27. D.A. Wink, and J.B. Mitchell Nitric oxide and cancer: an introduction Free Radic Biol Med 34 8 2003 951 954
28. D.A. Wink, Y. Vodovotz, J.A. Cook, M.C. Krishna, S. Kim, and D. Coffin The role of nitric oxide chemistry in cancer treatment Biochemistry (Mosc) 63 7 1998 802 809
29. L.M. Landino, B.C. Crews, M.D. Timmons, J.D. Morrow, and L.J. Marnett Peroxynitrite, the coupling product of nitric oxide and superoxide, activates prostaglandin biosynthesis Proc Natl Acad Sci USA 93 26 1996 15069 15074
30. Y.J. Surh, K.S. Chun, H.H. Cha, S.S. Han, Y.S. Keum, and K.K. Park Molecular mechanisms underlying chemopreventive activities of anti-inflammatory phytochemicals: down-regulation of COX-2 and iNOS through suppression of NF-kappa B activation Mutat Res 480-481 2001 243 268
31. U. Wenzel, S. Kuntz, U.J. De Sousa, and H. Daniel Nitric oxide suppresses apoptosis in human colon cancer cells by scavenging mitochondrial superoxide anions Int J Cancer 106 5 2003 666 675
32. C.V. Rao, C. Indranie, B. Simi, P.T. Manning, J.R. Connor, and B.S. Reddy Chemopreventive properties of a selective inducible nitric oxide synthase inhibitor in colon carcinogenesis, administered alone or in combination with celecoxib, a selective cyclooxygenase-2 inhibitor Cancer Res 62 1 2002 165 170
33. S. Ambs, W.P. Bennett, W.G. Merriam, M.O. Ogunfusika, S.M. Oser, and A.M. Harrington Relationship between p53 mutations and inducible nitric oxide synthase expression in human colorectal cancer J Natl Cancer Inst 91 1 1999 86 88
34. S.P. Hussain, P. Amstad, K. Raja, S. Ambs, M. Nagashima, and W.P. Bennett Increased p53 mutation load in noncancerous colon tissue from ulcerative colitis: a cancer-prone chronic inflammatory disease Cancer Res 60 13 2000 3333 3337
35. A.R. Amin, P. Vyas, M. Attur, J. Leszczynska-Piziak, I.R. Patel, and G. Weissmann The mode of action of aspirin-like drugs: effect on inducible nitric oxide synthase Proc Natl Acad Sci USA 92 17 1995 7926 7930
36. R.S. Farivar, and P. Brecher Salicylate is a transcriptional inhibitor of the inducible nitric oxide synthase in cultured cardiac fibroblasts J Biol Chem 271 49 1996 31585 31592
37. L. Sanchez de Miguel, T. de Frutos, F. Gonzalez-Fernandez, V. del Pozo, C. Lahoz, and A. Jimenez Aspirin inhibits inducible nitric oxide synthase expression and tumour necrosis factor-alpha release by cultured smooth muscle cells Eur J Clin Invest 29 2 1999 93 99